FDA Recalls Neostigmine Injectable Syringes Due to Sterility Assurance Deficiency
FDA is recalling Central Admixture Pharmacy Services' neostigmine injectable syringes due to lacking validation data for sterilization decontamination cycles, raising concerns about product sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable medication with inadequate sterilization validation. Although no illnesses or injuries have been reported, the lack of sterility assurance in an injectable product represents a significant potential for harm.
Plain-English summary
Central Admixture Pharmacy Services is recalling 6,468 neostigmine 5 mg/5mL syringes nationwide due to inadequate validation of the sterilization decontamination process used during drug preparation.
The manufacturer lacks validation data confirming that its decontamination cycles effectively ensure the sterility of the finished product. This deficiency means there is no assurance that the syringes are adequately sterilized, creating a potential contamination risk.
Healthcare facilities and providers who have received affected lots should identify them using the provided lot numbers and expiration dates, and stop using them immediately. They should contact Central Admixture Pharmacy Services or their distributor for return or replacement instructions.
Patients who have been administered doses from affected lots should consult their healthcare provider if they experience signs of infection.
The recalled product
- Product
- neostigmine 5 mg/5mL (1mg/mL) Syringe, Rx only, This drug was repacked by CAPS, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-6065-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable Medication
- Affected units
- 6,468
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 36-239285
- 36-239287
- Exp. 7/11/2023
- 36-239456
- Exp. 7/12/2023
- 36-239873
- Exp. 7/13/2023
- 36-240994
- 36-240995
- 36-240996
- 36-240997
- Exp. 7/18/2023
- 36-241447
- Exp. 7/20/2023
- 36-242407
- 36-242408
- Exp. 7/25/2023
- 36-246298
- Exp. 8/3/2023
- 36-248998
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 95 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 95 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility assurance
See all →- HighArrowhead DE LLC Recalls Arrow-LOK Implants Due to Sterility Assurance Concerns
FDA (Devices) · 2026-08-26
- SevereChloraPrep One-Step Applicators Recalled for Potential Packaging Seal Defects
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereChloraPrep One-Step Applicators Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2026-07-08
- SevereArrow drainage and thoracentesis kits contain recalled supplier drugs
FDA (Devices) · 2026-06-24